Tejnaksh Healthcare Ltd
Incorporated in 2008, Tejnaksh Healthcare
Ltd is in the business of Healthcare Services
and Pharmacies[1]
- Market Cap ₹ 47.5 Cr.
- Current Price ₹ 23.4
- High / Low ₹ 34.9 / 21.2
- Stock P/E 21.4
- Book Value ₹ 12.2
- Dividend Yield 0.00 %
- ROCE 10.5 %
- ROE 7.81 %
- Face Value ₹ 5.00
Pros
- Company has reduced debt.
- Debtor days have improved from 27.0 to 15.6 days.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -9.22% over past five years.
- Company has a low return on equity of 9.95% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|
4.75 | 7.28 | 14.14 | 19.76 | 17.12 | 11.96 | 12.68 | 11.73 | 12.18 | 12.55 | |
2.45 | 4.08 | 8.80 | 15.58 | 13.08 | 8.24 | 7.88 | 8.03 | 8.55 | 8.33 | |
Operating Profit | 2.30 | 3.20 | 5.34 | 4.18 | 4.04 | 3.72 | 4.80 | 3.70 | 3.63 | 4.22 |
OPM % | 48.42% | 43.96% | 37.77% | 21.15% | 23.60% | 31.10% | 37.85% | 31.54% | 29.80% | 33.63% |
0.03 | 0.19 | 0.39 | 1.55 | 0.34 | 0.13 | 0.11 | 0.31 | 0.31 | 0.30 | |
Interest | 0.00 | 0.20 | 0.98 | 0.78 | 0.76 | 0.50 | 0.48 | 0.62 | 0.66 | 0.56 |
Depreciation | 0.21 | 0.35 | 0.47 | 0.59 | 0.65 | 0.68 | 0.67 | 0.87 | 0.91 | 1.00 |
Profit before tax | 2.12 | 2.84 | 4.28 | 4.36 | 2.97 | 2.67 | 3.76 | 2.52 | 2.37 | 2.96 |
Tax % | 37.74% | 32.75% | 25.70% | 28.21% | 27.61% | 22.47% | 25.27% | 28.57% | 25.74% | |
1.32 | 1.82 | 3.18 | 3.14 | 2.15 | 2.07 | 2.81 | 1.79 | 1.77 | 2.26 | |
EPS in Rs | 0.65 | 0.90 | 1.42 | 1.49 | 1.03 | 1.01 | 1.34 | 0.83 | 0.88 | 1.13 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | -9% |
3 Years: | 1% |
TTM: | 10% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | -10% |
3 Years: | -5% |
TTM: | 113% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | -4% |
3 Years: | -26% |
1 Year: | -27% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 11% |
3 Years: | 10% |
Last Year: | 8% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 1.10 | 2.21 | 2.21 | 10.16 | 10.16 | 10.16 | 10.16 | 10.16 | 10.16 | 10.16 |
Reserves | 5.14 | 5.86 | 7.93 | 3.00 | 5.09 | 7.16 | 9.90 | 11.61 | 13.41 | 14.63 |
0.00 | 6.39 | 7.64 | 6.33 | 7.19 | 4.89 | 6.99 | 6.42 | 4.80 | 2.88 | |
0.60 | 1.07 | 1.98 | 2.78 | 2.47 | 2.36 | 2.56 | 3.04 | 2.99 | 4.41 | |
Total Liabilities | 6.84 | 15.53 | 19.76 | 22.27 | 24.91 | 24.57 | 29.61 | 31.23 | 31.36 | 32.08 |
3.34 | 13.60 | 15.33 | 16.97 | 17.37 | 15.04 | 15.38 | 23.42 | 23.22 | 24.08 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.39 | 0.65 | 0.79 | 8.89 | 0.95 | 1.07 | 0.00 |
Investments | 2.59 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
0.91 | 1.92 | 4.43 | 4.91 | 6.89 | 8.74 | 5.34 | 6.86 | 7.07 | 8.00 | |
Total Assets | 6.84 | 15.53 | 19.76 | 22.27 | 24.91 | 24.57 | 29.61 | 31.23 | 31.36 | 32.08 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|
3.67 | 2.25 | 4.49 | 3.15 | 1.16 | 1.18 | 9.21 | 2.12 | 4.21 | |
-3.26 | -8.03 | -3.24 | -1.55 | -1.21 | 1.56 | -10.59 | -1.40 | -1.22 | |
-0.13 | 6.43 | -0.66 | -2.09 | 0.10 | -2.80 | 1.62 | -1.20 | -2.27 | |
Net Cash Flow | 0.29 | 0.65 | 0.59 | -0.50 | 0.05 | -0.06 | 0.24 | -0.48 | 0.73 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|
Debtor Days | 0.00 | 0.00 | -0.77 | 3.51 | 11.30 | 14.34 | 16.41 | 49.16 | 15.58 |
Inventory Days | 98.06 | 130.36 | 220.84 | 254.58 | 179.69 | 283.89 | 185.07 | 173.44 | 232.80 |
Days Payable | 114.40 | 225.95 | 226.97 | 184.03 | 151.62 | 190.61 | 100.25 | 139.79 | 63.23 |
Cash Conversion Cycle | -16.34 | -95.60 | -6.91 | 74.06 | 39.38 | 107.62 | 101.23 | 82.82 | 185.15 |
Working Capital Days | -1.54 | 4.51 | -7.49 | 22.72 | 75.47 | 8.55 | 6.91 | 45.74 | 20.38 |
ROCE % | 29.19% | 32.23% | 27.11% | 17.45% | 13.97% | 17.03% | 11.13% | 10.48% |
Documents
Announcements
- Submission Of Un-Audited Financial Results (Standalone & Consolidated) For The Quarter Ended On 30Th September 2024. 14 Nov
-
Board Meeting Outcome for Outcome Of Board Meeting In Accordance With SEBI (Listing Obligations And
Disclosure Requirements) Regulations, 2015
14 Nov - Approved un-audited financial results for Q2 FY2024.
-
Board Meeting Intimation for Regulation 29 Of SEBI (LODR) Regulations, 2015 And Closure
Of Trading Window
7 Nov - Board meeting to approve financial results on Nov 14, 2024.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
20 Oct - Refer Compliance Certificate under Reg 74(5) in the letter attached.
-
Announcement Of Dr. Ashish Rawandale'S Appointment As President Of The Urological Society Of
India Under Regulation 30
13 Oct - Dr. Ashish Rawandale appointed President of Urological Society of India.
Annual reports
Concalls
-
Feb 2018TranscriptNotesPPT
Business Overview:[1][2]
THL provides hospital and healthcare service in Mumbai and other parts of Maharashtra. It has ~13 urology clinics, ~4 urology hospitals and ~2 dental super speciality clinics. Company also runs a teaching institute recognized by the Ministry of Health and Family welfare. It has more than 150 research papers, 23 innovations, 13 patents applied.